



## Disruption of the mu–delta opioid receptor heteromer

Brian F. O'Dowd<sup>a,b,\*</sup>, Xiaodong Ji<sup>b</sup>, Paul B. O'Dowd<sup>b</sup>, Tuan Nguyen<sup>a,b</sup>, Susan R. George<sup>a,b,c</sup>

<sup>a</sup> Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada M5S 1A8

<sup>b</sup> Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada M5S 1A8

<sup>c</sup> Department of Medicine, University of Toronto, Toronto, Ontario, Canada M5S 1A8

### ARTICLE INFO

#### Article history:

Received 26 April 2012

Available online 11 May 2012

#### Keywords:

G protein coupled receptors  
Mu and delta opioid receptor  
Nuclear localization  
Protein structure  
Heteromer  
Interacting amino acids  
G protein  
Dimers

### ABSTRACT

The crystal structure of the mu and kappa opioid receptors has revealed dimeric structural arrangements. Mu–delta receptors heteromers also exist and we have identified discrete cytoplasmic regions in each receptor required for oligomer formation. In the carboxyl tail of the delta receptor we identified three glycine residues (-GGG), substitution of any of these residues prevented heteromer formation. In intracellular loop 3 of both mu and delta receptors we identified three residues (-SVR), substitution of any of these residues prevented heteromer formation.

© 2012 Elsevier Inc. All rights reserved.

## 1. Introduction

The recently reported crystal structures of mu and kappa opioid receptors described the oligomeric arrangement of these receptors as pairwise association of monomers [1,2]. Many G protein coupled receptors (GPCRs) form heteromers [3,4] and our goal is understanding how these receptors interact and the physiological relevance of heteromers. We, and others, have reported mu and delta opioid receptors also exist as heteromers [5,6], and these receptor interactions generated novel pharmacology and functional properties (recently reviewed [7]). Thus mu–delta heteromers provide an additional drug target with possible relevance in analgesia, tolerance and drug dependence.

Mu and delta receptors share 65% overall amino acid homology with 82% homology in the transmembrane domains, 87% in intracellular loop 3 but only 17% in the cytoplasmic tail. Previously, we partially identified a structural region required for the mu–delta interaction, which was present in the distal portion of the carboxyl tail of the delta receptor [8]. A delta receptor 15 amino acid carboxyl tail truncation had reduced ability to co-immunoprecipitate the mu receptor and definitive binding data indicated

a lack of heteromer formation. Further structural details of the interaction sites of mu and delta receptor heteromers remained unknown.

In our ongoing investigations of receptor heteromer interactions we used a nuclear localization sequence (NLS) strategy; whereby an NLS was inserted into one of the receptors [9,10]. In previous investigations, the D2 dopamine–NLS receptor translocated the D1 dopamine receptor to the nucleus and thus provided a tool to study receptor:receptor dynamic interactions. By this means we successfully determined the structural basis for the D1–D2 dopamine receptor interaction. The precise contributions of cytoplasmic regions of these dopamine receptors to heteromer formation were identified [11].

In this report we determined the amino acids in the cytoplasmic regions of both delta and mu opioid receptors involved in heteromer formation. By changing a single identified amino acid in ic3 of mu or delta receptor or the carboxyl tail of delta receptor we prevented mu–delta heteromers from forming.

## 2. Materials and methods

### 2.1. Fluorescent proteins

cDNA sequences encoding GFP, RFP were obtained from Clontech (Palo Alto, CA), and the receptor constructs generated as described [9,11].

\* Corresponding author at: Department of Pharmacology, University of Toronto, 1 King's College Circle, Room 4353, Toronto, Ontario, Canada M5S 1A8. Fax: +1 416 971 2868.

E-mail address: [brian.odowd@utoronto.ca](mailto:brian.odowd@utoronto.ca) (B.F. O'Dowd).

## 2.2. Cell culture

HEK cells grown to confluence on 60 mm plates in minimum essential medium (MEM), and were transfected with 0.5–2 µg cDNA using Lipofectamine (Life technologies, Rockville, MD).

## 2.3. Microscopy

Live cells expressing GFP, RFP fusion proteins were visualized with a LSM510 Zeiss confocal laser microscope. In each experiment 5–8 fields, containing 50–80 cells per field were evaluated and the entire experiment was repeated several times ( $n = 3–5$ ).

## 2.4. DNA constructs

All the DNA encoding the GPCRs were of rat origin. Sequences encoding GPCRs were cloned into plasmids pEGFP, as described previously [11].

## 2.5. Receptor constructs

The mu and delta receptors were prepared using the Quick-change mutagenesis kit (Stratagene) according to the manufacturer's instructions, and as described [9,10]. Receptor DNA was subjected to PCR as previously reported [9,10]. The reaction mixture consisted of: H<sub>2</sub>O (32 µl), 10× Pfu buffer (Stratagene) (5 µl), dNTP (10 mM, 5 µl), DMSO (5 µl), oligonucleotide primers (100 ng, 1 µl each), DNA template (100 ng), Pfu enzyme (5 U). Total volume 50 µl. PCR conditions, one cycle at 94 °C for 2 min, 30–35 cycles at 94 °C for 30 s, 55 °C for 30 s, 72 °C for 1 min, per cycle, and then one cycle at 72 °C for 5 min. The NLS sequence was inserted into DNA encoding the mu opioid receptor by PCR [12].

## 3. Results

### 3.1. Expression of the mu-NLS receptor with the delta receptor

The mu receptor expressed in HEK cells was localized on the cell surface, while expression of mu-NLS receptor revealed localization in cytoplasm and nucleus, Fig. S1A. Cells expressing mu-NLS were treated with naloxone (100 nM), resulting in cell surface retention and no receptor in the nucleus, Fig. S1B. Following naloxone removal, the distribution of the receptor was altered, as the mu-NLS receptor translocated mainly to the cytoplasm and nucleus, Fig. S1C. Heteromer formation was monitored by the ability of mu-NLS receptors to transport the delta receptor to the nucleus, the mu-NLS receptor and the delta receptor are shown co-expressed in Fig. 1A, and also following antagonist treatment and removal, Fig. 1B. In each case co-translocation of the mu and delta receptors was observed, indicating formation of mu and delta receptor heteromers.

### 3.2. Identification of carboxyl tail delta receptor residues involved in heteromer formation

As we had previously identified the distal carboxyl tail of the delta receptor as being involved in heteromer formation [8] we wished to identify specific residues involved. The carboxyl tail extends ~52 amino acids, comprising 14% of the total receptor, Fig. 2. We prepared a 15 amino acid carboxyl tail deletion construct (C1), and this was expressed with the mu-NLS receptor. This delta receptor, C1, failed to show receptor heteromerization, thus confirming critical amino acids in this region were required in heteromer formation. Deletion of the terminal 6 amino acids from this carboxyl tail (-GGGAAA), C2, resulted in no heteromer formation,

this region is located 46 amino acids from the end of TM7. The terminal -AAA sequence was substituted (AAA to LLL), C3, and normal heteromer formation was observed. Whereas, substitution of three glycines with leucines, (C4, -LLLAAA) resulted in no heteromer formation, Fig. S1D. Thus these contiguous glycine residues were critical for delta interaction with the mu receptor. We prepared various additional constructs (Table 1) examining the role of each glycine, including C5 (AAG), C6 (GAG) Fig. 1C, C7 (AGG), and C8 (GGL) in each case no heteromers were formed. Also C12 and C13 (Table 1) we investigated the role of residues amino terminal to -GGG, with no effect on heteromer formation. Thus we identified three distal carboxyl tail residues (-GGG) and deletion of each residue prevented mu-delta heteromer formation.

### 3.3. Identification of mu opioid receptor residues involved in heteromer formation

To determine mu receptor residues involved in forming heteromers we prepared four constructs with deletions in the mu receptor carboxyl tail (C1–C4 in Table 2). This mu receptor carboxyl tail is 59 amino acids in length and comprises 15% of the receptor. Expression of each construct with delta receptor retained heteromer formation, thus eliminating 45 amino acids in the mu receptor carboxyl tail from direct involvement in heteromer formation.

We prepared a series of mu receptor constructs with deletions in ic3, this loop contains only ~23 amino acids, and comprises 6% of the receptor, Fig. 2. Each of the ic3 receptor constructs were expressed with the delta receptor. A deletion of 10 amino acids (L1, Table 2), from the mid-section of ic3 had no effect on mu-delta heteromer formation. A mu receptor with 3 substituted amino acids from the carboxyl region of ic3 (L2), also formed heteromers. However substitution of three residues, -SVR, from the amino terminal region of ic3, (L3), failed to form heteromers (Fig. 1D). Thus amino acids maintaining mu-delta receptor heteromer formation were contained in this discrete -SVR region. This ic3 sequence was located 4 amino acids from TM5 (Fig. 2). By substituting each of the three amino acids in this sequence, L4 (-AVR), and L5 (SAR), L6 (SVA) we determined that substitution of any of the residues in -SVR resulted in heteromer disruption. In the adjacent amino terminal sequence -RLK SVR, we substituted -RAK (L12) and -RLR (L11), each construct formed heteromers. A mu receptor with a conserved substitution of the serine with threonine -TVR, L10, did not form heteromers, also a conserved substitution of lysine for arginine (in -SVR) did not form heteromers, L8. Thus from a total of ~23 amino acids in ic3 of the mu receptor three amino acids were identified to be involved in forming heteromers. Thus we demonstrated a single residue change in mu ic3 prevented mu-delta heteromer formation.

### 3.4. Identification of ic3 delta opioid receptor residues involved in heteromers

The ic3 of delta receptor is 87% identical with mu, delta ic3 also contains the -SVR sequence, Fig. 2, in the similar location. We prepared a delta receptor with a substitution -SVR to -AAA in ic3 (Table 1), this delta receptor (L1) was expressed with mu receptor and failed to form heteromers, Fig. 1E.

## 4. Discussion

There are significant accomplishments regarding mu-delta receptor heteromer interactions reported. (i) We identified three contiguous glycines, -GGG, located in the delta receptor carboxyl tail required to form heteromers. (ii) We determined that each gly-

Download English Version:

<https://daneshyari.com/en/article/10760657>

Download Persian Version:

<https://daneshyari.com/article/10760657>

[Daneshyari.com](https://daneshyari.com)